



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Ly93

<b>Cat. No.:</b>	HY-114307		
<b>CAS No.:</b>	1883528-69-5		
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>20</sub> N <sub>2</sub> O <sub>2</sub>		
<b>Molecular Weight:</b>	332.4		
<b>Target:</b>	Others		
<b>Pathway:</b>	Others		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 250 mg/mL (752.11 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	3.0084 mL	15.0421 mL	30.0842 mL
		5 mM	0.6017 mL	3.0084 mL	6.0168 mL
10 mM		0.3008 mL	1.5042 mL	3.0084 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.08 mg/mL (6.26 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (6.26 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.08 mg/mL (6.26 mM); Clear solution</li> </ol>				

### BIOLOGICAL ACTIVITY

<b>Description</b>	Ly93 is a selective and orally active sphingomyelin synthase 2 (SMS2) inhibitor, with an IC <sub>50</sub> of 91 nM <sup>[1]</sup> .
<b>In Vivo</b>	<p>Ly93 (100 mg/kg, i.g. once daily for 7 days) significantly decreases the plasma SM levels of C57BL/6J mice<sup>[1]</sup>.</p> <p>Ly93 dose-dependently attenuates the atherosclerotic lesions in the root and the entire aorta as well as macrophage content in lesions, in apolipoprotein E gene knockout mice<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

Animal Model:	C57BL/6J mice <sup>[1]</sup> .
Dosage:	100 mg/kg.
Administration:	I.G. (gavage) once daily for 7 days.
Result:	Significantly decreased the plasma SM levels compared with vehicle group.
Animal Model:	ApoE KO mice (eight-week-old) <sup>[1]</sup> .
Dosage:	12.5 or 40 mg/kg.
Administration:	I.G. (gavage) once daily.
Result:	The levels of ALT and AST in the plasma of apoE KO mice did not show statistic changes when compared with the control group.

## CUSTOMER VALIDATION

- Clin Transl Med. 2023 Mar;13(3):e1229.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Li Y, et al. Discovery, synthesis and anti-atherosclerotic activities of a novel selective sphingomyelin synthase 2 inhibitor. Eur J Med Chem. 2019 Feb 1;163:864-882.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA